Search

PureTech Health Plc

Fermé

126.4 0.8

Résumé

Variation du prix de l'action

24h

Actuel

Min

121.6

Max

126.6

Chiffres clés

By Trading Economics

Revenu

-42M

Ventes

288K

Marge bénéficiaire

-14,504.514

Employés

90

EBITDA

-65M

Dividendes

By Dow Jones

Prochains Résultats

30 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

296M

Ouverture précédente

125.6

Clôture précédente

126.4

PureTech Health Plc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 avr. 2025, 23:27 UTC

Actualités

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28 avr. 2025, 23:07 UTC

Actualités

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28 avr. 2025, 23:03 UTC

Résultats

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28 avr. 2025, 23:47 UTC

Market Talk

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28 avr. 2025, 23:17 UTC

Résultats

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28 avr. 2025, 23:17 UTC

Résultats

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28 avr. 2025, 23:13 UTC

Résultats

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28 avr. 2025, 23:13 UTC

Résultats

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28 avr. 2025, 23:13 UTC

Résultats

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28 avr. 2025, 23:13 UTC

Résultats

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28 avr. 2025, 23:08 UTC

Résultats

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28 avr. 2025, 23:08 UTC

Résultats

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28 avr. 2025, 23:08 UTC

Résultats

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28 avr. 2025, 23:04 UTC

Résultats

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28 avr. 2025, 23:04 UTC

Résultats

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28 avr. 2025, 23:04 UTC

Résultats

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28 avr. 2025, 23:04 UTC

Résultats

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28 avr. 2025, 23:00 UTC

Résultats

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28 avr. 2025, 23:00 UTC

Résultats

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28 avr. 2025, 23:00 UTC

Résultats

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28 avr. 2025, 23:00 UTC

Résultats

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28 avr. 2025, 22:57 UTC

Actualités

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28 avr. 2025, 22:55 UTC

Résultats

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28 avr. 2025, 22:55 UTC

Résultats

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28 avr. 2025, 22:55 UTC

Résultats

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28 avr. 2025, 22:52 UTC

Résultats

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28 avr. 2025, 22:52 UTC

Résultats

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28 avr. 2025, 22:52 UTC

Résultats

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28 avr. 2025, 22:52 UTC

Résultats

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28 avr. 2025, 22:46 UTC

Résultats

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

PureTech Health Plc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.